Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?

This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exc...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in radiation oncology Vol. 27; no. 3; pp. 229 - 239
Main Authors: Siva, Shankar, Slotman, Ben J.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01.07.2017
Subjects:
Dose Fractionation
Hematology, Oncology and Palliative Medicine
Humans
Immunotherapy
Lung Neoplasms - mortality
Lung Neoplasms - radiotherapy
Lung Neoplasms - secondary
Molecular Targeted Therapy
Radiology
Radiosurgery - methods
ISSN:1053-4296, 1532-9461, 1532-9461
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1053-4296
1532-9461
1532-9461
DOI:10.1016/j.semradonc.2017.03.003